このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

REGENXBIO マネジメント

マネジメント基準チェック /24

REGENXBIO'sの CEO はKen Millsで、 Mar2009年に任命され、の在任期間は 15.25年です。の年間総報酬は$ 5.92Mで、 11.4%給与と88.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.56%を直接所有しており、その価値は$ 3.20M 。経営陣と取締役会の平均在任期間はそれぞれ7.3年と7.8年です。

主要情報

Ken Mills

最高経営責任者

US$5.9m

報酬総額

CEO給与比率	11.4%
CEO在任期間	15.3yrs
CEOの所有権	0.6%
経営陣の平均在職期間	7.3yrs
取締役会の平均在任期間	7.8yrs

経営陣の近況

Recent updates

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Oct 03

Regenxbio: A Transformative Year

Sep 15

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Aug 29

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Aug 03

CEO報酬分析

REGENXBIO の収益と比較して、Ken Mills の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$260m
Dec 31 2023	US$6m	US$677k	-US$263m
Sep 30 2023	n/a	n/a	-US$261m
Jun 30 2023	n/a	n/a	-US$274m
Mar 31 2023	n/a	n/a	-US$270m
Dec 31 2022	US$6m	US$651k	-US$280m
Sep 30 2022	n/a	n/a	US$74m
Jun 30 2022	n/a	n/a	US$91m
Mar 31 2022	n/a	n/a	US$101m
Dec 31 2021	US$9m	US$632k	US$128m
Sep 30 2021	n/a	n/a	-US$212m
Jun 30 2021	n/a	n/a	-US$145m
Mar 31 2021	n/a	n/a	-US$121m
Dec 31 2020	US$8m	US$613k	-US$111m
Sep 30 2020	n/a	n/a	-US$91m
Jun 30 2020	n/a	n/a	-US$135m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$6m	US$596k	-US$95m
Sep 30 2019	n/a	n/a	-US$64m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$5m	US$546k	US$100m
Sep 30 2018	n/a	n/a	US$80m
Jun 30 2018	n/a	n/a	US$78m
Mar 31 2018	n/a	n/a	US$53m
Dec 31 2017	US$3m	US$530k	-US$73m

報酬と市場: Kenの総報酬 ($USD 5.92M ) は、 US市場 ($USD 2.45M ) の同規模の企業の平均を上回っています。

報酬と収益: Kenの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Ken Mills (49 yo)

15.3yrs

在職期間

US$5,916,712

報酬

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer, President and Director at REGENXBIO Inc., (formerly REGENX Biosciences, LLC) since March 2009 and serves as its Chairman since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kenneth Mills	President	15.3yrs	US$5.92m	0.56% $ 3.2m
Vittal Vasista	Executive VP & CFO	14.8yrs	US$2.62m	0.38% $ 2.2m
Curran Simpson	Executive VP & COO	no data	US$2.95m	0.051% $ 293.7k
Olivier Danos	Executive VP & Chief Scientific Officer	7.3yrs	US$2.99m	0.058% $ 335.7k
Stephen Pakola	Executive VP & Chief Medical Officer	5.2yrs	US$3.31m	0% $ 0
Patrick Christmas	Executive VP & Chief Legal Officer	7.8yrs	US$3.44m	0.046% $ 266.7k
Shiva Fritsch	Chief Communications & People Officer	6.7yrs	データなし	データなし
Ram Palanki	Executive VP of Commercial Strategy & Operations	5.8yrs	データなし	データなし

7.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: RGNXの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Kenneth Mills	President	15.3yrs	US$5.92m	0.56% $ 3.2m
David Stump	Independent Director	8.7yrs	US$339.98k	0.0061% $ 35.2k
George Migausky	Independent Director	2.8yrs	US$339.98k	0.0061% $ 35.2k
Argeris Karabelas	Independent Director	9.1yrs	US$352.48k	0.0061% $ 35.2k
Inder Verma	Member of Scientific Advisor	no data	データなし	データなし
Allan Fox	Independent Director	15.3yrs	US$354.98k	6.42% $ 37.0m
Judith Swain	Member of Scientific Advisor	no data	データなし	データなし
Alexandra Glucksmann	Independent Director	6.1yrs	US$327.48k	0.0061% $ 35.2k
Daniel Tassé	Lead Independent Director	7.8yrs	US$334.98k	0.0061% $ 35.2k
Jean Bennett	Independent Director	2.8yrs	US$324.98k	0.0061% $ 35.2k
Jennifer Zachary	Independent Director	2yrs	US$329.98k	0.0041% $ 23.5k

7.8yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: RGNXの取締役会は経験豊富であると考えられます ( 7.8年の平均在任期間)。

REGENXBIO マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

REGENXBIO Inc. Announces Chief Executive Officer Changes

President notifies of intention to sell stock

President exercised options and sold US$216k worth of stock

REGENXBIO Inc., Annual General Meeting, May 31, 2024

President exercised options and sold US$272k worth of stock

President exercised options and sold US$195k worth of stock

Recent updates

REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Inc. Announces Chief Executive Officer Changes

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

President notifies of intention to sell stock

Consensus revenue estimates fall by 27%

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

First quarter 2024 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

President exercised options and sold US$216k worth of stock

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

President exercised options and sold US$272k worth of stock

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Price target increased by 7.3% to US$38.55

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

Consensus EPS estimates fall by 21%

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

President exercised options and sold US$195k worth of stock

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

President notifies of intention to sell stock

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Consensus revenue estimates fall by 16%

Executive VP & Chief Medical Officer notifies of intention to sell stock

President notifies of intention to sell stock

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Price target decreased by 10% to US$36.40

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Consensus EPS estimates upgraded to US$4.84 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Consensus EPS estimates fall by 19%

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Consensus EPS estimates upgraded to US$4.26 loss

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 21%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

REGENXBIO Inc. Announces Executive Promotions

Executive VP & Chief Medical Officer notifies of intention to sell stock

REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease

Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I

Price target decreased to US$44.70

Consensus revenue estimates fall by 14%

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Investor sentiment improved over the past week

Regenxbio: A Transformative Year

マネジメント基準チェック /24